2. Academic Validation
  3. Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2

Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2

  • Bioorg Med Chem Lett. 2006 Apr 15;16(8):2109-12. doi: 10.1016/j.bmcl.2006.01.066.
Tao Jiang 1,  Kelli L Kuhen,  Karen Wolff,  Hong Yin,  Kimberly Bieza,  Jeremy Caldwell,  Badry Bursulaya,  Tove Tuntland,  Kanyin Zhang,  Donald Karanewsky,  Yun He
Affiliations

Affiliation

  • 1 Genomics Institute of the Novartis Research Foundation (GNF), 10715 John Jay Hopkins Drive, San Diego, CA 92121, USA.
PMID: 16464578 DOI: 10.1016/j.bmcl.2006.01.066
Abstract

A series of heterocycle-containing oxindoles was synthesized and their HIV Antiviral activities were assessed. Some of these analogs exhibited potent inhibitory activities against both wild-type virus and a number of drug-resistant mutant viruses. In addition, oxindole 9z also showed promising pharmacokinetics.

Figures